PE20170687A1 - Proteinas de enlace a cd127 - Google Patents
Proteinas de enlace a cd127Info
- Publication number
- PE20170687A1 PE20170687A1 PE2017000247A PE2017000247A PE20170687A1 PE 20170687 A1 PE20170687 A1 PE 20170687A1 PE 2017000247 A PE2017000247 A PE 2017000247A PE 2017000247 A PE2017000247 A PE 2017000247A PE 20170687 A1 PE20170687 A1 PE 20170687A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- refers
- chain variable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UN ANTICUERPO HUMANIZADO QUE COMPRENDE: A) UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE LAS SIGUIENTES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD i) CDRH1 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 2, ii) CDRH2 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 3, Y iii) CDRH3 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 4, O 132 A 137; Y B) UNA REGION VARIABLE DE CADENA LIGERA QUE COMPRENDE LAS SIGUIENTES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD iv) CDRL1 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 5, v) CDRL2 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 6, Y vi) CDRL3 CON UNA SECUENCIA DE AMINOACIDOS DE SEQ ID NO: 7. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO ANTICUERPO SE ENLAZA AL RECEPTOR DE IL-7 HUMANO (CD127) SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES TAL COMO ESCLEROSIS MULTIPLE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29901010P | 2010-01-28 | 2010-01-28 | |
| PCT/US2011/022507 WO2011094259A2 (en) | 2010-01-28 | 2011-01-26 | Cd127 binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170687A1 true PE20170687A1 (es) | 2017-06-13 |
Family
ID=44320081
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012001071A PE20121702A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace cd127 |
| PE2017000247A PE20170687A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace a cd127 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012001071A PE20121702A1 (es) | 2010-01-28 | 2011-01-26 | Proteinas de enlace cd127 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9150653B2 (es) |
| EP (1) | EP2528947A4 (es) |
| JP (1) | JP5850860B2 (es) |
| KR (1) | KR20130028055A (es) |
| CN (1) | CN102812046B (es) |
| AR (1) | AR080027A1 (es) |
| AU (1) | AU2011209713B2 (es) |
| BR (1) | BR112012018914A2 (es) |
| CA (1) | CA2787070A1 (es) |
| CL (1) | CL2012002081A1 (es) |
| CO (1) | CO6592067A2 (es) |
| CR (1) | CR20120404A (es) |
| EA (1) | EA023700B1 (es) |
| IL (1) | IL220899A (es) |
| MA (1) | MA34004B1 (es) |
| MX (1) | MX339083B (es) |
| MY (1) | MY160590A (es) |
| NZ (1) | NZ601271A (es) |
| PE (2) | PE20121702A1 (es) |
| SG (1) | SG182590A1 (es) |
| TW (1) | TWI489996B (es) |
| UA (1) | UA104663C2 (es) |
| UY (1) | UY33202A (es) |
| WO (1) | WO2011094259A2 (es) |
| ZA (1) | ZA201205624B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9217040B2 (en) | 2011-01-14 | 2015-12-22 | The Regents Of The University Of California | Therapeutic antibodies against ROR-1 protein and methods for use of same |
| EP2583980A1 (en) * | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| WO2016059512A1 (en) | 2014-10-18 | 2016-04-21 | Pfizer Inc. | Anti-il-7r antibody compositions |
| WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| JP7183042B2 (ja) | 2016-01-07 | 2022-12-05 | ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド | 眼の免疫炎症性疾患のための治療法 |
| HUE045183T2 (hu) | 2016-02-29 | 2019-12-30 | Ose Immunotherapeutics | Az IL7 receptor extracelluláris doménjének alfa lánca ellen termeltetett nem antagonista hatású antitestek és ezek rákterápiában való használata |
| RU2769352C2 (ru) | 2016-12-09 | 2022-03-30 | Осе Иммьюнотерапьютикс | Антитела и полипептиды, направленные против cd127 |
| US20210095283A1 (en) * | 2018-01-04 | 2021-04-01 | Avidity Biosciences, Inc. | Heteroduplex nucleic acid molecules and uses thereof |
| JP7285936B2 (ja) * | 2019-01-22 | 2023-06-02 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用 |
| EP3986570A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Compositions |
| MX2021015763A (es) | 2019-06-21 | 2022-04-18 | Sorriso Pharmaceuticals Inc | Polipeptidos. |
| JP2022537780A (ja) | 2019-06-21 | 2022-08-29 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| WO2023232826A1 (en) | 2022-05-30 | 2023-12-07 | Ose Immunotherapeutics | Biomarkers of il7r modulator activity |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
| US20030229208A1 (en) * | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| CA2033082A1 (en) | 1989-06-15 | 1990-12-16 | Linda S. Park | Interleukin-7 receptors |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methoden zur Herstellung humanisierter Antikörper |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク，インコーポレイテッド | 二特異的免疫アドヘジン |
| ES2108460T3 (es) | 1993-06-03 | 1997-12-16 | Therapeutic Antibodies Inc | Fragmentos de anticuerpos en terapeutica. |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5795737A (en) | 1994-09-19 | 1998-08-18 | The General Hospital Corporation | High level expression of proteins |
| CZ297045B6 (cs) * | 1994-12-23 | 2006-08-16 | Smithkline Beecham Corporation | Hlodavcí neutralizacní monoklonální protilátka, zpusob pro její produkci, kompozice s jejím obsahema pouzití, hybridom a jím produkovaná protilátka,fab fragment, komplementaritu urcující region, molekula nukleové kyseliny a její sekvence, plasmid a |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6277599B1 (en) | 1996-05-04 | 2001-08-21 | Zeneca Limited | Anti-CEA antibody designated 806.077, hybridoma and method of manufacture |
| AU743616B2 (en) | 1997-02-07 | 2002-01-31 | Merck & Co., Inc. | Synthetic HIV gag genes |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9806530D0 (en) | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1173765B1 (de) | 1999-04-13 | 2007-01-03 | Wilex AG | Diagnostischer und therapeutischer einsatz von antikörpern gegen den urokinase-rezeptor |
| US7504256B1 (en) | 1999-10-19 | 2009-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing polypeptide |
| AU2002218166A1 (en) | 2000-09-08 | 2002-03-22 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| KR100960560B1 (ko) | 2002-09-27 | 2010-06-03 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 및 그의 제조 방법 |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| EP1641818B1 (en) | 2003-07-04 | 2008-12-03 | Affibody AB | Polypeptides having binding affinity for her2 |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| MXPA06006406A (es) | 2003-12-05 | 2007-03-21 | Adnexus Therapeutics Inc | Inhibidores de receptores de factor de crecimiento endotelial vascular tipo 2. |
| AU2005269759A1 (en) | 2004-07-21 | 2006-02-09 | Glycofi, Inc. | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
| WO2006052660A2 (en) * | 2004-11-04 | 2006-05-18 | Childrens Hospital Los Angeles Research Institute | Il-7 receptor blockade to suppress immunity |
| TWI419904B (zh) * | 2006-12-18 | 2013-12-21 | Genentech Inc | 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途 |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| WO2009094148A2 (en) | 2008-01-22 | 2009-07-30 | Biogen Idec Ma Inc. | Ron antibodies and uses thereof |
| UY32038A (es) | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
-
2011
- 2011-01-26 PE PE2012001071A patent/PE20121702A1/es not_active Application Discontinuation
- 2011-01-26 CN CN201180015856.0A patent/CN102812046B/zh not_active Expired - Fee Related
- 2011-01-26 US US13/574,847 patent/US9150653B2/en not_active Expired - Fee Related
- 2011-01-26 SG SG2012053138A patent/SG182590A1/en unknown
- 2011-01-26 KR KR1020127022553A patent/KR20130028055A/ko active IP Right Grant
- 2011-01-26 MY MYPI2012003394A patent/MY160590A/en unknown
- 2011-01-26 CA CA2787070A patent/CA2787070A1/en not_active Abandoned
- 2011-01-26 WO PCT/US2011/022507 patent/WO2011094259A2/en active Application Filing
- 2011-01-26 UA UAA201209254A patent/UA104663C2/ru unknown
- 2011-01-26 US US13/013,993 patent/US8940303B2/en not_active Expired - Fee Related
- 2011-01-26 MX MX2012008765A patent/MX339083B/es active IP Right Grant
- 2011-01-26 AR ARP110100251A patent/AR080027A1/es unknown
- 2011-01-26 EA EA201290589A patent/EA023700B1/ru not_active IP Right Cessation
- 2011-01-26 TW TW100102962A patent/TWI489996B/zh not_active IP Right Cessation
- 2011-01-26 NZ NZ601271A patent/NZ601271A/en not_active IP Right Cessation
- 2011-01-26 BR BR112012018914A patent/BR112012018914A2/pt not_active IP Right Cessation
- 2011-01-26 PE PE2017000247A patent/PE20170687A1/es not_active Application Discontinuation
- 2011-01-26 AU AU2011209713A patent/AU2011209713B2/en not_active Ceased
- 2011-01-26 UY UY0001033202A patent/UY33202A/es not_active Application Discontinuation
- 2011-01-26 EP EP11737543.6A patent/EP2528947A4/en not_active Withdrawn
- 2011-01-26 MA MA35147A patent/MA34004B1/fr unknown
- 2011-01-26 JP JP2012551247A patent/JP5850860B2/ja not_active Expired - Fee Related
-
2012
- 2012-07-12 IL IL220899A patent/IL220899A/en not_active IP Right Cessation
- 2012-07-24 CO CO12124175A patent/CO6592067A2/es active IP Right Grant
- 2012-07-25 ZA ZA2012/05624A patent/ZA201205624B/en unknown
- 2012-07-26 CL CL2012002081A patent/CL2012002081A1/es unknown
- 2012-07-31 CR CR20120404A patent/CR20120404A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| CO2020014727A2 (es) | Anticuerpo anti proteína reguladora de señales alfa sirpαlfa | |
| PE20142242A1 (es) | Anticuerpos humanos anti-cd27, metodos, y usos | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| PE20080181A1 (es) | Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| AR081556A1 (es) | Proteinas de union al antigeno humanizadas | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| ES2571129T3 (es) | Anticuerpos anti-CTLA4 humanizados | |
| JP2020500538A5 (es) | ||
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
| PE20140133A1 (es) | Nuevas proteinas de union a antigenos | |
| PE20141660A1 (es) | PROTEINAS DE UNION A ANTIGENO DE TNF-ALFA CON UNION A FcRn INCREMENTADA | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20130159A1 (es) | Anticuerpos anti-cd40 | |
| NZ623347A (en) | Novel anti-dr5 antibody | |
| RU2011129204A (ru) | Антитела против ангиопоэтина-2 человека | |
| NZ629829A (en) | Anti-c5a antibodies and methods for using the antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |